Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2024-03-23 | 2024-02-20 |
| Drug Identification Number | 02247459 | 02247459 |
| Brand name | CHORIONIC GONADOTROPIN FOR INJECTION, USP | CHORIONIC GONADOTROPIN FOR INJECTION, USP |
| Common or Proper name | CHORIONIC GONADOTROPIN FOR INJECTION, USP | CHORIONIC GONADOTROPIN FOR INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | CHORIONIC GONADOTROPIN | CHORIONIC GONADOTROPIN |
| Strength(s) | 10000UNIT | 10000UNIT |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR |
| Packaging size | 10000UNIT | 10000UNIT |
| ATC code | G03GA | G03GA |
| ATC description | GONADOTROPHINS AND OTHER OVULATION STIMULANTS | GONADOTROPHINS AND OTHER OVULATION STIMULANTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2024-02-26 | 2024-02-26 |
| Estimated end date | 2024-03-25 | 2024-03-25 |
| Actual end date | 2024-03-22 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | We regret to advise that we will be experiencing a backorder on this product. | We regret to advise that we will be experiencing a backorder on this product. |
| Health Canada comments |